Daniel C. Pevear
About Daniel C. Pevear
Daniel C. Pevear Company
Daniel C. Pevear is the Founder and Senior Vice President, Biology and Grants Development. His company ventures focus on anti-infectives drug discovery and development. Pevear holds a prominent position, leveraging over 25 years of experience in the field to guide the company's direction and research milestones.
Daniel C. Pevear Title
Daniel C. Pevear holds the title of Founder and Senior Vice President, Biology and Grants Development. In this role, he spearheads various scientific initiatives and oversees strategic grant development processes.
Daniel C. Pevear Education and Expertise
Daniel C. Pevear earned his Ph.D. in Viral Immunology from Rensselaer Polytechnic Institute in 1984. He further honed his expertise as a Postdoctoral Fellow of the National Multiple Sclerosis Society at Northwestern University Medical School from 1985 to 1988. With over 25 years of experience, Pevear has substantial expertise in anti-infectives drug discovery and development.
Daniel C. Pevear Background
Daniel C. Pevear has a robust background in pharmaceutical research and development. He worked at the Sterling Winthrop Research Institute from 1988 to 1994 before becoming a founding scientific team member at ViroPharma Inc. in 1994. During his tenure at ViroPharma, he led a team of over 30 scientists and advanced a first-in-class inhibitor for common cold viruses through NDA filing. He also directed research efforts at Progenics Pharmaceuticals on HIV and Hepatitis C. Pevear was the Director of Biology at Protez Pharmaceuticals, advancing a beta-lactamase inhibitor into preclinical development.
Daniel C. Pevear Achievements
Daniel C. Pevear has published over 80 papers in peer-reviewed journals and has written more than six reviews. He served as Principal Investigator and contributed to six SBIR-Advanced Technology awards. In 2005, he served on an NIH Center for Scientific Review Special Emphasis Panel for AIDS SBIR applications. Pevear directed a billion-dollar collaboration with Alnylam Pharmaceuticals on RNA interference technology while at Novartis Pharmaceuticals and co-led the team advancing a first-in-class beta-lactamase inhibitor at Protez Pharmaceuticals.